BRIM Biotechnology (TPE:6885) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6885 BRIM Biotechnology Inc TPE:6885
40 GF Score
Price NT$20.55
GF Value NT$707.93
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is BRIM Biotechnology Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

TPE:6885
40GF Score
BRIM Biotechnology Inc TPE:6885
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BRIM Biotechnology (TPE:6885) Overvalued in 2026?

Based on GuruFocus' analysis, BRIM Biotechnology stock appears to be undervalued. The current stock price of NT$20.55 is trading 97.1% below its estimated GF Value™ of NT$707.93. GuruFocus considers BRIM Biotechnology to be Possible Value Trap.

Key valuation signals for TPE:6885:

  • Interest Received:
  • GF Value™: NT$707.93 vs. price of NT$20.55 (97.1% below fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the TPE:6885 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BRIM Biotechnology Business Description

Address Alley 30, Lane 358, Ruiguang Road, 8th Floor, No.1, Neihu District, Taipei, TWN, 11492
BRIM Biotechnology Inc is engaged in the research and development of new drug translation, genetic testing services, research and development services in natural and engineering sciences, and medical laboratory services. The Group has two reportable operating segments: BRIM's main business is new drug translational development services, and Compass's main business is gene sequencing and testing technology services. It generates the majority of its revenue from the BRIM segment. Geographically, it operates in Taiwan, Japan, and the USA. It generates the majority of its revenue from Taiwan.
40GF Score

Get the complete analysis for TPE:6885

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$20.55
Price
NT$707.93
GF Value